Talavera JO, Rivas-Ruiz R, Pérez-Rodríguez M, Roy-Garcia IA, Palacios-Cruz L

Language: Spanish
References: 48
Page: 168-175
PDF size: 233.94 Kb.

ABSTRACT

A clinical research question requires the concurrence of clinical experience and knowledge on methodology and statistics in that who formulates it. Initially, a research question should have a structure that clearly establishes what is that which is being sought (consequence or outcome), in whom (baseline status), and by action of what (maneuver). Subsequently, its reasoning must explore four aspects: feasibility and reasonableness of the questioning, lack of a prior answer, relevance of the answer to be obtained, and applicability. Once these aspects are satisfactorily covered, the question can be regarded as being "clinically relevant", which is different from being statistically significant, which refers to the probability of the result being driven by chance, which does not reflect the relevance of the question or the outcome. One should never forget that every maneuver entails adverse events that, when serious, discredit good results. It is imperative to have the possible answer estimated from within the structure of the question. The function of clinical research is to corroborate or reject a hypothesis, rather than to empirically test to find out what the outcome is.

REFERENCES

1. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed). 1988;296:313-316.

2. Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med.1989;321:129-135.

3. The Medical Research Council’s General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet. 1998; 351:233-241.

4. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-2559.

5. Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? JAMA. 2000;283:2701-2711.

6. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.

7. Buckley LF, Dixon DL, Wohlford GF, Wijesinghe DS, Baker WL, Van-Tassell BW. Intensive versus standard blood pressure control in SPRINT-Eligible Participants of ACCORD-BP. Diabetes Care. 2017;40:1733-1738.

8. Mi MY, Mukamal KJ. Comment on Buckley et al. Intensive versus standard blood pressure control in SPRINT-Eligible Participants of ACCORD- BP. Diabetes Care 2017;40:1733-1738. Diabetes Care. 2018; 41:e84-e85.

9. Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA. 2000;283:1016-1024.

10. Talavera JO. Investigación clínica I. Diseños de investigación. Rev Med Inst Mex Seguro Soc. 2011;49:53-58.

11. Pérez-Rodríguez M, Palacios-Cruz L, Rivas-Ruiz R, Talavera JO. Investigación clínica XXIV. Del juicio clínico a la ética en investigación en humanos. Rev Med Inst Mex Seguro Soc. 2014;52 666-672.

12. Taveras EM, Marshall R, Sharifi M, Avalon E, Fiechtner L, Horan C, et al. Comparative effectiveness of clinical-community childhood obesity interventions: a randomized clinical trial. JAMA Pediatr. 2017;171:e171325.

13. Rivas-Ruiz R, Talavera JO. Investigación clínica VII. Búsqueda sistemática: cómo localizar artículos. Rev Med Inst Mex Seguro Soc. 2012;50:53‑58.

14. Feinstein AR. The architecture of clinical research. Clin Pharmacol Therap. 1970;11.

15. Hulley SB, Cummings SR, Browner WS, Grady DG, Newman TB. Designing clinical research: an epidemiologic approach. EE. UU.: Lippincott Williams & Wilkins; 2001.

16. Talavera JO, Wacher-Rodarte NH, Rivas-Ruiz R. Investigación clínica III. Estudios de causalidad. Rev Med Inst Mex Seguro Soc. 2011;49 289‑294.

17. Portney LG, Watkins MP. Foundations of clinical research. Applications to practice. EE. UU.: F.A. Davis Company; 2015.

18. Bradford-Hill A. The environment and disease: association or causation? Proc R Soc Med. 1965;58:295-300.

19. Zur-Hausen H. Papillomaviruses in the causation of human cancers a brief historical account. Virology. 2009;384:260-265.

20. Narisawa-Saito M, Kiyono T. Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins. Cancer Sci. 2007;98:1505-1511.

21. Milner JJ, Rebeles J, Dhungana S, Stewart DA, Summer SC, Meyers MH, et al. Obesity increases mortality and modulates the lung metabolome during pandemic H1N1 influenza virus infection in mice. J Immunol. 2015; 194:4846-4859.

22. Kornum JB, Nørgaard M, Dethlefsen C, Due KM, Thomsen RW, Overvad K, et al. Obesity and risk of subsequent hospitalisation with pneumonia. Eur Respir J. 2010;36:1330-1336.

23. Quinn G, Shin CH, Maguire MG, Stone RA. Myopia and ambient lighting at night. Nature. 1999;399:113-114.

24. Gwiazda J, Ong E, Held R, Thorn F. Vision: myopia and ambient night- time lighting. Nature. 2000 (404):143-144.

25. Fergusson D, Glass KC, Hutton B, Shapiro S. Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding? Clin Trials. 2005;2:218-229.

26. Vanderpool HY, editor. The ethics of research involving human subjects: facing the 21st century. EE. UU.: University Publishing Group; 1996.

27. Instituto Nacional de Salud Pública. Encuesta Nacional de Salud y Nutrición de Medio Camino 2016. Informe final de resultados. México: Instituto Nacional de Salud Pública/Secretaría de Salud; 2016.

28. Bertado-Cortés B, Villamil-Osorio L, Carrera-Pineda R, Martínez-Cortés C, Guerrero-Cantera J. Características clínicas y sociodemográficas de los pacientes con esclerosis múltiple. Rev Med Inst Mex Seguro Soc. 2016; 54:186-190.

29. Vásquez-Garibay EM, Miranda-Ríos L, Romero-Velarde E, Nuño-Cosío ME, Campos-Barrera L, Nápoles-Rodríguez F, et al. Desmedro, sobrepeso y obesidad durante la transición nutricia en escolares de Arandas, Jalisco, México. Rev Med Inst Mex Seguro Soc. 2018;56:6‑11.

30. Keller AC, Knaub LA, Miller MW, Birdsey N, Klemm DJ, Reusch JE. Saxagliptin restores vascular mitochondrial exercise response in the Goto-Kakizaki rat. J Cardiovasc Pharmacol. 2015;65(2):137-147.

31. Del Prato S, Fleck P, Wilson C, Chaudhari P. Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. Diabetes Obes Metab. 2016;18:623-627.

32. Kaur K, Likar N, Dang A, Kaur G. Efficacy and safety of canagliflozin among patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Indian J Endocrinol Metab. 2015;19:705-721.

33. Castelán-Martínez OD, Jiménez-Méndez R, Rodríguez-Islas F, Fierro- Evans M, Vázquez-Gómez BE, Medina-Sansón A, et al. Hearing loss in Mexican children treated with cisplatin. Int J Pediatr Otorhinolaryngol. 2014;78:1456-1460.

34. Rivas-Ruiz R, Guzmán-Cabañas JM, Párraga-Quiles MJ, Ruiz-González MD, Huertas-Muñoz MD, Alvarez-Marcos R, et al. Utility of the clinical risk index for babies (CRIB) as a predictor of hospital death and intraventricular hemorrhage in very low birth weight and extremely low birth weight neonates. An Pediatr (Barc). 2007;66:140-145.

35. Granados-García V, Sánchez-García S, Ramírez-Aldana R, Zúñiga-Trejo C, Espinel-Bermúdez MC. Costos por hospitalización de adultos mayores en un hospital general regional del IMSS. Rev Med Inst Mex Seguro Soc. 2018;56:S65-S70.

36. Barquera S, Campos-Nonato I, Aguilar-Salinas C, López-Ridaura R, Arredondo A, Rivera-Dommarco J. Diabetes in Mexico: cost and management of diabetes and its complications and challenges for health policy. Global Health. 2013;9:3.

37. González-Canudas J, Iglesias-Chiesa JM, Romero-Antonio Y, Chávez- Cortes C, Gay-Molina JG, Rivas-Ruiz R. Cost-effectiveness in the detection of influenza H1N1: clinical data versus rapid tests. Rev Panam Salud Publica. 2011;29:1-8.

38. Castelán-Martínez OD, Hernández-Carbajal E, Contreras-García CE, Ojeda-Luna NG, Rivas-Ruiz R. Eficacia del tratamiento ambulatorio de la neumonía adquirida en la comunidad: revisión sistemática y metaanálisis. Rev Med Inst Mex Seguro Soc. 2016;54:128-136.

39. Miller ME, Williamson JD, Gerstein HC, Byington RP, Cushman WC, Ginsberg HN, et al. Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial. Diabetes Care. 2014;37:634-643.

40. Beddhu S, Rocco MV, Toto R, Craven TE, Greene T, Bhatt U, et al. Effects of intensive systolic blood pressure control on kidney and cardiovascular outcomes in persons without kidney disease: a secondary analysis of a randomized trial. Ann Intern Med. 2017;167:375-383.

41. Woodward-Lopez G, Gosliner W, Au LE, Kao J, Webb KL, Sagatov RD, et al. Community characteristics modify the relationship between obesity prevention efforts and dietary intake in children: the Healthy Communities Study. Pediatr Obes. 2018;13:46-55.

42. Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Brethauer SA, Navaneethan SD, et al. Bariatric surgery versus intensive medical therapy for diabetes: 3-year outcomes. N Engl J Med. 2014;370 2002-2013.

43. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-1847.

44. Peacock WF, De-Marco T, Fonarow GC, Diercks D, Wynne J, Apple FS, et al. Cardiac troponin and outcome in acute heart failure. N Engl J Med. 2018;358:2117-2125.

45. Rivas-Ruiz R, Clark P, Talavera JO, Huitrón G, Tamayo JA, Salmerón J. Bone speed of sound throughout lifetime assessed with quantitative ultrasound in a Mexican population. J Clin Densitom. 2015;18 68-75.

46. Herzog JI, Schmahl C. Adverse childhood experiences and the consequences on neurobiological psychosocial, and somatic conditions across the lifespan. Front Psychiatry. 2018;9:420.

47. Riglin L, Collishaw S, Thapar AK, Dalsgaard S, Langley K, Smith GD, et al. Association of genetic risk variants with attention -deficit/hyperactivity disorder trajectories in the general population. JAMA Psychiatry. 2016;73:1285-1292.

48. Gómez-Coronado N, Sethi R, Bortolasci CC, Arancini L, Berk M, Dodd S. A review of the neurobiological underpinning of comorbid substance use and mood disorders. J Affect Disord. 2018;241:388-401.